Interleukin-12 is detectable in sera of patients with multiple sclerosis - association with chronic progressive disease course?

1999 ◽  
Vol 6 (5) ◽  
pp. 591-596 ◽  
Author(s):  
Christoph Heesen ◽  
Frank Sieverding ◽  
Benedikt Gustav Heinrich Schoser ◽  
Bijan Hadji ◽  
Klaus Kunze
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Disease ◽  
Interleukin 12 ◽  
Disease Course ◽  
Chronic Progressive Disease

scholarly journals The effectiveness of physical factors used in the treatment of patients with Multiple Sclerosis. Literature review

2015 ◽  
Vol 29 (3) ◽  
pp. 35-42
Author(s):  
Jolanta Zwolińska ◽  
Andrzej Kwolek ◽  
Monika Gąsior
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Disease ◽  
Physical Factors ◽  
Functional Capability ◽  
Physical Treatment ◽  
Fatal Disease ◽  
Current State ◽  
Chronic Progressive Disease ◽  
Physical Treatments ◽  
Selection Of

AbstractIntroduction: Multiple Sclerosis (MS) is a chronic progressive disease of the nervous system which etiology is still unknown. Environmental factors, genetic predisposition and complex autoimmune reactions play a significant role in its pathogenesis. MS is not a fatal disease, but patients often require constant medical care and complex social welfare. Physiotherapy conducted at every stage of the disease depends on the current state of a patient and their functional capability and gradually occurring disorders and dysfunctions. Physical therapy is an important element of the therapy.Aim: To evaluate the usefulness of physical treatments used in the treatment of the MS patients.Material and methods: An analysis of domestic and foreign literature published between 2004 and 2014. The following databases were searched: PubMed, Science Direct, Termedia, Polish Medical Bibliography, Cochrane. The papers concerning the use of physical treatment as monotherapy and combination therapy were included.Summary and conclusions: Numerous research confirm both safety and efficacy of physical methods used in treatment of the MS patients. The implementation of research on the mechanism of action and effectiveness of physical factors, which are well-designed in terms of methodology, allows for the selection of the optimal physical procedure. Modern equipment and current methods of physiotherapy change views on the previously used treatments, their methodology and application.

121. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis

2009 ◽  
Vol 16 (3) ◽  
pp. 467
Author(s):  
Fotini Pittas ◽  
Anne-Louise Ponsonby ◽  
Ingrid van der Mei ◽  
Bruce V. Taylor ◽  
Leigh Blizzard ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Prospective Cohort ◽  
Progressive Disease ◽  
Disease Course

scholarly journals Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis

Neurology ◽  
2015 ◽  
Vol 85 (8) ◽  
pp. 722-729 ◽  
Author(s):  
Martina Novotna ◽  
M. Mateo Paz Soldán ◽  
Nuhad Abou Zeid ◽  
Nilufer Kale ◽  
Melih Tutuncu ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Disease ◽  
Disease Course ◽  
Early Relapse

Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature

2019 ◽  
Vol 34 (12) ◽  
pp. 705-712 ◽  
Author(s):  
Anna Jeong ◽  
Denise M. Oleske ◽  
Joan Holman
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Confidence Interval ◽  
Progressive Disease ◽  
Pediatric Population ◽  
Population Based ◽  
Disease Course ◽  
Relapsing Remitting ◽  
Pediatric Neurologist ◽  
Pediatric Onset

Multiple sclerosis onset in youth is increasingly recognized. A systematic review was conducted to assess incidence and prevalence of pediatric-onset multiple sclerosis, focusing on occurrence by age subgroups and disease course. A literature search for the period 1965-2018 was carried out, selecting population-based studies of multiple sclerosis in individuals aged 19 years and younger. Nineteen studies met inclusion criteria. One pediatric neurologist extracted the data. Overall incidence ranged from 0.05 (95% confidence interval 0.03-0.08) to 2.85 (95% confidence interval 2.83-2.86) per 100 000 children and overall prevalence from 0.69 (95% confidence interval 0.58-0.80) to 26.92 (95% confidence interval 26.61-27.23) per 100 000 children. Incidence increased with age. The female-male ratio increased from 1.2:1 in children <12 years old to 2.8:1 in children ≥12 years old. Ten studies (n=521 children) reported disease course. Seven studies found only relapsing-remitting disease and 3 studies found primary-progressive disease in 3.0% to 6.7%. Two secondary-progressive disease cases were identified. Epidemiologic data aid in understanding the magnitude of multiple sclerosis and its clinical phenotypes, for planning for new disease-modifying therapies in the pediatric population.

scholarly journals CSF Myelin Basic Protein Levels in Acute Optic Neuritis and Multiple Sclerosis

1983 ◽  
Vol 10 (4) ◽  
pp. 235-238 ◽  
Author(s):  
K.G. Warren ◽  
Ingrid Catz ◽  
T.A. McPherson
Keyword(s):  
Multiple Sclerosis ◽  
Optic Neuritis ◽  
Myelin Basic Protein ◽  
Progressive Disease ◽  
Basic Protein ◽  
Internuclear Ophthalmoplegia ◽  
Protein Levels ◽  
Acute Optic Neuritis ◽  
Chronic Progressive Disease

SUMMARY:Normal CSF-MBP levels as determined by a RIA were <6.2 ng/ml CSF (mean 3.9). Eighty percent of patients with acute optic neuritis have CSF-MBP levels greater than 6.2 ng/ml (mean 7.6 ng/ml CSF). Five of 7 patients with acute internuclear ophthalmoplegia due to an initial exacerbation of demyelination have CSF-MBP levels above 6.2 ng/ml (mean 6.8 ng/ml). Fifty percent of MS patients with chronic progressive disease have CSF-MBP levels above 6.2 ng/ml (mean 6.7 ng/ml). MS patients experiencing monosymptomatic exacerbations show elevated CSF-MBP levels in 75% of cases (mean 8.2 ng/ml). MS patients experiencing polysymptomatic exacerbations show significantly higher levels of CSF-MBP (mean 22.3 ng/ml) than the patients with monosymptomatic exacerbations. Ninety-five percent of MS patients experiencing polysymptomatic exacerbations have elevated levels of CSF-MBP.

Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis

2001 ◽  
Vol 7 (5) ◽  
pp. 285-289 ◽  
Author(s):  
R Egg ◽  
M Reindl ◽  
F Deisenhammer ◽  
C Linington ◽  
T Berger
Keyword(s):  
Multiple Sclerosis ◽  
Significant Relationship ◽  
Progressive Disease ◽  
Basic Protein ◽  
Intravenous Immunoglobulins ◽  
Myelin Oligodendrocyte Glycoprotein ◽  
Disease Course ◽  
Mog Antibodies ◽  
Demyelinating Process ◽  
Myelin Antigens

In a subset of multiple sclerosis (MS) patients antibodies against myelin antigens seem to be important in the demyelinating process. In this study we investigated IgM, IgA and IgG serum antibodies against the myelin oligodendrocyte glycoprotein (MOG) and the myelin basic protein (MBP) in 261 MS patients. Seventy-two per cent had anti-MOG antibodies, 59% were anti-MBP seropositive. The dominating antibody was anti-MOG IgM. A significant relationship between IgA and a progressive disease course was found. The predominance of IgG1 together with the significantly associated occurrence of IgG3 against MOG corresponds to the prevailing IgG1 and IgG3 isotypes in other autoimmune diseases. Patients who actually suffered from a relapse were significant more often anti-MOG and anti-MBP IgG3 seropositive than those in remission. However, patients treated either with intravenous immunoglobulins or interferon-b showed a significant reduction of anti-MOG IgG3 antibodies.

scholarly journals Тhе genetic epidemiology of multiple sclerosis

2000 ◽  
Vol XXXII (1-2) ◽  
pp. 81-81
Author(s):  
A. Compston
Keyword(s):  
Multiple Sclerosis ◽  
Nervous System ◽  
Peripheral Nervous System ◽  
Genetic Epidemiology ◽  
Progressive Disease ◽  
Multiple Lesions ◽  
Chronic Progressive Disease

Multiple sclerosis is a chronic progressive disease of the nervous system, proceeding with exacerbations and remissions, or steadily progressively, with multiple lesions in the central and peripheral nervous system.

Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review

2021 ◽  
pp. 135245852110665
Author(s):  
Sara Cavaco ◽  
Inês Ferreira ◽  
Inês Moreira ◽  
Ernestina Santos ◽  
Raquel Samões ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Dysfunction ◽  
Retrospective Review ◽  
Progressive Disease ◽  
Disease Course ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Study Results ◽  
Clinical Records

Background: Cognitive dysfunction as a predictor of clinical progression and mortality in multiple sclerosis (MS) is still a matter of debate. Objective: The aim of this study was to explore the long-term outcome associated with neuropsychological performance in a cohort of patients with MS. Methods: A series of 408 MS patients had previously undergone a comprehensive neuropsychological assessment and a contemporaneous neurological evaluation (T1). A retrospective review of the clinical records was conducted 102–192 months after T1. Demographic and clinical data regarding the last clinical appointment with EDSS measurement (T2) were collected and the date of the last clinical contact or death (TS) was recorded. Results: This review revealed that cognitive dysfunction (T1) was associated with higher odds of transitioning from relapsing–remitting course to a progressive disease course (adjusted odds ratio (OR) = 2.29, p = 0.043) and higher hazard of death in the total sample (adjusted hazard ratio (HR) = 3.07, p = 0.006) and the progressive disease course subgroup (adjusted HR = 3.68, p = 0.007), even when adjusting for other covariates. Discussion: The study results demonstrate that cognitive dysfunction in MS is predictive of poorer prognosis and mortality.

Sign in / Sign up

Export Citation Format

Share Document